Diagnostic expansion in clinical trials: Myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were

Go Nishikawa; Vinay Prasad

doi:10.1136/bmj.k3783

Diagnostic expansion in clinical trials: Myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were

Go Nishikawa, Vinay Prasad

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Article number	k3783
Journal	BMJ (Online)
Volume	362
DOIs	https://doi.org/10.1136/bmj.k3783
State	Published - 2018

ASJC Scopus subject areas

General Medicine

Access to Document

10.1136/bmj.k3783

Cite this

@article{ae55039374c54d71b67bf54745b2d20e,

title = "Diagnostic expansion in clinical trials: Myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were",

author = "Go Nishikawa and Vinay Prasad",

note = "Funding Information: Data sharing and patient involvement in developing trial protocol may ameliorate these concerns Contributors and sources: GN and VP have an interest in evidence based medicine and outcome adjudication. VP has published many articles on trial methods and evidence. They have worked together on this and several papers. Competing interests: We have read and understood BMJ policy on declaration of interests and declare that VP is funded by the Laura and John Arnold Foundation and receives royalties for his book Ending Medical Reversal. VP has received honorariums for lectures to universities, non-profit medical centres, non-profit groups, and professional societies. VP is a writer for Medscape. Provenance and peer review: Not commissioned; externally peer reviewed",

year = "2018",

doi = "10.1136/bmj.k3783",

language = "English (US)",

volume = "362",

journal = "BMJ (Online)",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Diagnostic expansion in clinical trials

T2 - Myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were

AU - Nishikawa, Go

AU - Prasad, Vinay

N1 - Funding Information: Data sharing and patient involvement in developing trial protocol may ameliorate these concerns Contributors and sources: GN and VP have an interest in evidence based medicine and outcome adjudication. VP has published many articles on trial methods and evidence. They have worked together on this and several papers. Competing interests: We have read and understood BMJ policy on declaration of interests and declare that VP is funded by the Laura and John Arnold Foundation and receives royalties for his book Ending Medical Reversal. VP has received honorariums for lectures to universities, non-profit medical centres, non-profit groups, and professional societies. VP is a writer for Medscape. Provenance and peer review: Not commissioned; externally peer reviewed

PY - 2018

Y1 - 2018

UR - http://www.scopus.com/inward/record.url?scp=85053695808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053695808&partnerID=8YFLogxK

U2 - 10.1136/bmj.k3783

DO - 10.1136/bmj.k3783

M3 - Article

C2 - 30232089

AN - SCOPUS:85053695808

SN - 0959-8146

VL - 362

JO - BMJ (Online)

JF - BMJ (Online)

M1 - k3783

ER -

Diagnostic expansion in clinical trials: Myocardial infarction, stroke, cancer recurrence, and metastases may not be the hard endpoints you thought they were

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this